Drug intelligence / Profile preview

BCM-1032

Development stage: Preclinical
Lead developer: Biocidium Biopharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

BCM-1032 is an investigational drug developed by Biocidium Biopharmaceuticals. It is currently in the preclinical stage and is being explored for use as an intravenous therapy targeting various indications, with a focus on infectious diseases caused by Gram-negative bacteria. The specific mechanism of action and molecular target have not been disclosed publicly. The drug is part of Biocidium's pipeline aimed at addressing multi-drug resistant infections, particularly those involving challenging Gram-negative pathogens[1][2].

Beyond the preview

Go deeper on BCM-1032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-1032.

Explore the full profile